一. Oncology Clinical Trial(XMRP):

Breast Cancer

1. A Randomized, Open-Label, Multicenter, phaseⅢ study of Epoetin Alfa plus Standard Supportive Care versus Standard Supportive Care in Anemic Patients With Metastatic Breast Cancer Receiving First-Line Standard Chemotherapy (J&J,Global study, 2006)

2. An observational, multicenter study of Zometa in bone metastatic breast cancer, prostate cancer or multiple myeloma patients under conditions of normal practice. (Novartis, PMS study, 2006)

3. A phase III, multicenter, randomized, placebo-controlled trial evaluating the efficacy and safety of Bevacizumab in combination with chemotherapy regimens in subjects with previously treated metastatic breast cancer. (Genetech, Global study, 2007)

Colon-Rectum Cancer

1. Open, Randomized, Controlled, Multicenter phaseⅢ Study Comparing 5-FU/FA plus Irinotecan plus cetuximab versus 5-FU/FA plus Irinotecan as first-line treatment for epidermal growth factor receptor-expressing metastatic colorectal cancer (Crystal Study, Global study, Merck, 2005)

2. Open-Label, Non-comparative, Multicenter, phaseⅢb study, An expanded access program of Avastin (Bevacizumab) in patients with metastatic cancer of the colon or rectum (Roche, EAP study, 2005)

3.A Multicenter Phase II Study of Oral Thalidomide in Addition to oxaliplatin in Combination with 5–Fuorouracil (5-FU)/Leucovorin (LV) as First-line Chemotherapy in Treatment of  Advanced Colorectal Cancer (TTY, Taiwan multicenter study, 2006)

4. An open label, multi-center phase 2 study of oxaliplatin in combination with 5-FU/leucovorin as adjuvant chemotherapy in patients with colon cancer. (TTY, Taiwan multicenter study, 2006)

5. A phase II trial of neoadjuvant therapy of Bevacizumab in combination with oxaliplatin and Capecitabine (XELOX) in metastatic colorectal cancer with unresectable liver metastasis. (Roche, Global study, 2007)

6. A multicenter, randomized, double-blind, phase 3 study of Sunitinib in metastatic colorectal cancer patients receiving FOLFIRI as first line treatment. (Pfizer, Global, 2007)

7. A phase I/II trial of DCB-CA1 in combination of 5-FU plu leucovorin in the treatment for metastatic colorectal cancer patients who have failed first line and second line chemotherapy. (in preparation, DCB)

Lung Cancer

1. A phase III, international, randomized, double-blind, parallel-group, multi-center study to asscess the efficacy of ZD6474 (Zactima) plus best supportive care versus placebo plus best supportive care in patients with locally advanced or metastatic stage III-IV non-small cell lung cancer after prior therapy with an epidermal growth factor Tyrosine Kinase inhibitor (EGFR TKI) (Astra Zeneca, Global study, 2007)

Liver Cancer

1. A Phase 1/2 study in locally advanced, recurrent, metastatic hepatocellular carcinoma, evaluating the safety, pharmacokinetics, and anti-tumor activity of ADH300004 (eniluracil) with escalating doses of 5-FU. (Adherex, Global, study, in preparation)

2. A phase 2 study of Tegafur/Uracil plus thalidomide for the treatment of advanced or metastatic hepatocellular carcinoma. (TTY, Taiwan multicenter study, 2006)

Gastric Cancer

1. Open-Label, Non-comparative, Multicenter, phaseⅠ/Ⅱ study of Oxaliplatin〈OXALIP〉with Oral Tegafur-Uracil 〈UFUR〉and Leucovorin in Patients with Advanced Gastric cancer (TTY, Taiwan multicenter study, 2005)

2. A randomized Phase II study of PEP02, Irinotecan or Docetaxel as a second line therapy in patients with locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. (PharmaEngine, Global study, in preparation)

3. A Phase II study of weekly oxaliplatin combined with Docetaxel as first line treatment in patients with advanced gastric cancer. (Aventis-Sinofi, Taiwan multicenter study, 2007)

4. A phase II study of Docetaxel and Cisplatin plus oral UFUR and leucovorin as first line chemotherapy in patients with locally advanced or metastatic gastric cancer. (TTY, Taiwan multicenter study, 2007) 

Bilt Duct Cancer

1.      A Phase II trial of oxaliplatin with high dose of 5-FU and leucovorin in the first line treatment of inoperable, locally advanced or metastatic biliary tract cancer. (TTY, 2005)

Bladder Cancer

1. Open-Label, Non-comparative, Multicenter, phaseⅡ study of Tegafur/Uracil (UFUR) in combination with Gemcitabine and Cisplatin in Patients with Advanced Bladder Cancer (Transitional Cell Carcinoma) (TTY, 2005)

Lymphoma

1. A phase II study of concurrent chemoradiation for the untreated, localized nasal NK/T-cell lymphoma (TCOG, 2006) (NHRI T1405)

Nasopharyngeal Carcinoma

1. A multicenter phase III trial comparing induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in stage IV nasopharyngeal carcinoma. (TCOG, 2006) (NHRI T1303)

2. A trial of Gemcitabine in combination with cisplatin for treatment of recurrent/metastatic nasopharyngeal carcinoma. (TTY, 2006) 

二. Basic Research Trial(NMRPG/CMRPG):

國科會研究計劃

1. 成體幹細胞之分化及癌化間對位性基因體關聯性之探討(97-3112-B-194-001-) (2006/5/1 至 2009/4/30)

2. 人類間質幹細胞在體外培養與進行肝臟細胞分化時基因體穩定性與重組之研究 (95-2745-B-182A-147-MY2) (2006/8/1 至 2008/7/31)

3. 發展雙腫瘤發病時間之統計模型以探討成人第二惡性腫瘤之危險因子: 台灣 

   健保資料庫的應用與分析 (95-2118-M-182-001-) (2006/8/1 至 2007/7/31)

4.Use of EBV DNA, VEGF and EBV capsid antigen in monitoring and risk stratification of  patients with nasopharyngeal carcinoma. (95-2314-B-371-012), (2006/8- 2007/7)

Chang Gung Research Trial

1. Predictive prognostic values of topoisomerase II alpha and beta-catenin mRNA and protein expression level in newly diagnosed acute myeloid leukemia. CMRPG650021

    (2006/5-2007/4)

2. Isolation and characterization of colon-rectal carcinoma stem cells. (2007/6-2010/5)

3. Measurement of circulating endothelial cells (CECs) and endothelial progenitor cells        (CEPs) as a surrogate biomarker in peripheral blood for monitoring tumor relapse and disease progression in colorectal cancer. (2007/6-2010/5)

三. Journal Publications(2002~2007): 

1. Chen CC, Yang CF, Lee KD, You JY, Yu YB, Ho CH, Tzeng TH, Chau WK, Hsu HC,Gau     JP. Complex karyotypes confer poorer survival in adult acute myeloid leukemia harboring   

    unfavorable cytogenetic abnormalities. Cancer Genet Cytogenet. (Accepted, 2007)

2. Weekly Paclitaxel in Women with Heavily Pretreated Metastatic Breast Cancer: A Retropective Analysis of Cases Treated at Chang-Gung Memorial Hospital. C-H Lu,Y-C Lin, H-K Chang.  Chang-Gung Med J 2007;33-40

3. Transcutaneous Arterial Embolization to Control Massive Tumor Bleeding in Head and Neck Cancer: 63 Patients' Experience from a Single Medical Center. W-C Chou, C-H Lu, G Lin, Y-S Hong, P-T Chen, H-C Hsu, J-S Chen, K-Y Yeh, H-M Wang, C-C Liaw.  Support Care in Cancer ( published online, Mar. 2007)

4. Chen MF, Chen WC, Wu WT, Lin PY, Shau H,i Liao SK, Yang CT and Lee KD. P53 status is a major determinant of the effects of decreasing peroxiredoxin I expression on tumor growth and response of lung cancer cells to treatment. International Journal of Radiation Oncology, Biology, Physics 66:1461-1472, 2006

5. Lin CT, Lin WH, Lee KD and Tzeng PY.  DNA Mismatch Repair as an Effector for Promoting Phorbol Ester-induced Apoptotic DNA Damage and Cell Killing: Implications in Tumor Promotion. International Journal of Cancer 15;119(8):1776-84. 2006 Oct

6. Lin JT, Yeh KT, Fan SY, Chang CC.  Fulminant but reversible interstitial pulmonary     

fibrosis associated with imatinib mesylate.  Leukemia & Lymphoma, 2006, 47(8): 693-5.

7. Chen CC, Lee KD, Yang CF, Gau JP. A novel chromosomal abnormality involving 2q37 in myeloid malignancies. Ann Hematol 2006;85:333-334.

8. Gau JP, Chen CC, Hsu HC, Ho CH, Chau WK, You JY, Yu YB. Nucleotide changes around the splicing acceptor of intron 24 in the factor VIII gene and its impact on splicing. Blood Coagul Fibrin 2006;17:53-56.

9. Lee KD, Chen HW, Chen CC, Shih YC, Liu HK, Cheng ML. Construction and characterization of a novel fusion protein consisting of anti-CD3 antibody fused to recombinant interleukin-2. Oncol Rep 2006;15:1211-1216.

10. Chen MF, Lin CT, Chen WC, Yang CT, Chen CC, Liao SK, Liu JM, Lu CH, Lee KD. The sensitivity of human mesenchymal stem cells to ionizing radiation. Int J Radiat Oncol Biol Phys 2006;66:244-253.

11. Chen CC, Yang CF, Yang MH, Lee KD, Kwang WK, Yu YB, You JY, Tzeng TH, Ho CH, Chau WK, Hsu HC, Gau JP. Pre-treatment prognostic factors and treatment outcome in elderly patients with de novo acute myeloid leukemia. Ann Oncol 2005;16:1366-73.

12. Chen CC, Lee KD, Gau JP, Yu YB, You JY, Lee SC, Hsu HC, Chau WK, Ho CH.  Plasma antigen levels of thrombin-activatable fibrinolysis inhibitor did not differ in patients with       or without disseminated intravascular coagulation. Ann Hematol 2005;84:675-80.

13. Chen CC, Chang JY, Liu KJ, Chan C, Ho CH, Lee SC, Chen LT. Hepatocellular carcinoma associated with acquired von Willebrand disease and extreme thrombocytosis. Ann Oncol   2005;16:988-9.

14. Yang MH, Yen CC, Chiang SC, Bai LY, Lee KD, Hsiao LT, Chao TC, Wang WS, Liu JH, Chiou TJ, Chen PM. Prognostic significance of clonal diversity of immunoglobulin gene rearrangement in patients with diffuse large B-cell lymphoma. Oncology Report 13:503-508, 2005

15. HoCH, Chau WK, Hsu HC, Gau JP, You JY, Chen CC. Predictive risk factors and prevalence of malignancy in patients with iron deficiency anemia in Taiwan. Am J Hematology  78:108-12, 2005 

16. Lin JT, Wang WS, Yen CC , Liu JH, Chen PM, Chiou TJ.  Stage IV thymic carcinoma: a study of 21 patients.  Am J Med Science 2005, 330(4):172-5.

17. Lin JT, Wang WS, Yen CC , Liu JH, Chen PM, Chiou TJ.  Metastatis-induced acute pancreatitis in Lung Cancer.  Adv Therapy, 2005, 22(3):225-33.

18. Lin JT, Wang WS, Yen CC , Liu JH, Chen PM, Chiou TJ.  Outcome of colorectal cancer in patients younger than 40 years of age.  J Gastroenterol Hepatol, 2005, 20(6):900-5.

19. Chung CY, Yeh KT, Hsu NC, Chang JH, Lin JT, Horng HC, Chang CS. Expression of c-kit protooncogene in hepatocellular carcinoma.  Cancer Letter 2005, 217(2): 231-6.

20. Lee KD, Kuo TK, Whang-Peng J, Chung YF, Lin CT, Chou SH, Chen JR, Chen YP, Lee  

      OK. In Vitro Hepatic Differentiation of Human Mesenchymal Stem Cells. Hepatology  23;40(6):1275-1284 , 2004 Dec

21. OK Lee, T Kuo, WM Chen, Lee KD,SL Shieh, TH Chen. Isolation of multipotent mesenchymal stem cells from umbilical cord blood. Blood 103(5): 1669-1675, 2004 Mar

22. Liu JM, Chen LT, Li AF, Wu CW, Lan C, Chung TR, Shiah HS, Lee KD, Liu TW, Peng JW. Prognostic Implications of the Expression of erbB2, Topoisomerase II{alpha} and  Thymidylate Synthase in Metastatic Gastric Cancer After Fluorouracil-based Therapy. Jpn J  Clin Oncol. 34(12):727-32, 2004 Dec

23. Lin JT, Yen CC , Chiou TJ, Liu JH, Chen PM, Wang WS.  Erythema nodosum associated with carcinoid tumor.  Clin & Exp Dermatol. 2004, 29(4):426-7.

24. Lin JT, Yen CC, Wang WS, Chiou TJ, Liu JH, Chen PM.  Pulmonary nocardiosis in a CML relapse           patient undergoing imatinib after bone marrow transplantation. Ann  Hematol, 2004, 83(7): 444-6.

25. You JY, Chi KH, Yang MH, Chen CC, Ho CH, Chau WK, Hsu HC, Gau JP, Tzeng CH, Liu JH, Chen      PM, Chiou TJ.  Radiation Therapy versus Chemotherapy as Initial Treatment for Localized Nasal NK/T       Cell Lymphoma: a Single Institute Survey in Taiwan. Ann Oncol   2004;15:618-25

26. You JY, Yu YB, Chen PC, Tsay SH, Chen CC, Ho CH, Chau WK, Hsu HC, Gau JP, Tzeng TH: Donor        lymphocyte infusion induced acute hepatitis. J Chin Med Assoc.  2004;67:411-5.

27. Chen CC, You JY, Ho CH. The aPTT assay as a monitor heparin anticoagulation efficacy in clinical               settings. Adv Ther 2003; 20:231-6.

28. Chen CC, Gau JP, Ho CH, Lin JS, Chiou HJ, Lirng JF. Aggressive multiple myeloma with brain      involvement in a young patient. J Chin Med Assoc 2003; 66:177-80.

29. Lin JT, Wang WS, Yen CC, Chiou TJ, Liu JH, Chen PM.  All-trans-retinoid acid  

     increased the Notch transcription expression in acute promyelocytic leukemia cells. Adv  

     Therapy. 2003,20(6): 337-344.

30. Lin JT, Wang WS,Yen CC , Chiou TJ, Liu JH, Chen PM. Chryseobacterium indologenes  Bacteremia in a Bone Marrow Transplant Recipient with Chronic Graft-versus-Host Disease.  Scan J Inf Dis, 2003, 35(11-12): 882-3.

31. Lin JT, Yen CC, Wang WS, Chiou TJ, Liu JH, Wu HT, Chen PM.  Case report: Unusual peritoneal spreading by metastatic osteosarcoma of the tibia. Br J Radiol. 2003 May;76(905):337-8.

32. Lin JT, Wang SJ, Fuh JL, Hsiao LT, Lirng JF, Chen PM.  Prolonged reversible  

      vasospasm in cyclosporin A-induced encephalopathy.  Am J Neuroradiol. 2003 Jan;24 

      (1):102-4.

33. Gau JP, Hsu HC, Ho CH, Chau WK, Chen CC, You JY: Rapid detection of intron 22 inversions of the factor VIII gene in Chinese patients with severe hemophilia A. J Chin Med Assoc 2003; 66:518-522.

34. Hsiao LT, Lin JT, Yu IT, Chiou TJ, Liu JH, Yen CC, Wang WS, Chen PM.  High serum hepatocyte growth factor level in patients with non-Hodgkin's lymphoma.  Eur J Haematol. 2003 May;70(5):282-9.

35. Ho CH, You JY, Chau WK, Hsu HC, Gau JP, Chen CC. Yu TJ. Diagnostic value of serum transferrin receptor and glycosylated hemoglobin on hemolytic anemia. Ann Hematol 2003;82:228-30.

36. Lee KD, Liu TW, Wu CW, Tiu CM, Liu JM, Chung TR, Chang JY, Whang-Peng J, Chen LT. Non-surgical treatment for afferent loop syndrome in recurrent gastric cancer complicated by peritoneal carcinomatosis- Percutaneous transhepatic duodenal drainage followed by 24-hour infusion of high-dose fluorouracil and leucovorin. Annals of Oncology 13(7):1151-1155, 2002 Jul

37. Ho CH, Lin MW, You JY, Chen CC, Yu TJ. Variations of prothrombin time and  

     international normalized ratio in patients treated with warfarin. Thromb Res 2002;107:277-80.

38. You JY, Chen CC, Lin EK, Ho CH. The characteristics of megaloblastic anemia  

 associated with thalassemia. Haematologica 2002;87:550-1.

39. Chen CC, Ho CH. Chronic lymphocytic leukemia improved using splenectomy. A case report and literature review. J Med Sci 2002;22:39-42.

40. Lin JT, Wang WS, Yen CC, Chiou TJ, Liu JH, Hsiao LT, Yang MH, Chao TC, Tai CJ, Chen PM.  Myelodysplastic syndrome complicated by autoimmune hemolytic anemia: remission of refractory anemia following mycophenolate mofetil. Ann Hematol. 2002 Dec;81(12):723-6.

41. Lin JT, Wang WH, Yen CC, Yu IT, Chen PM.  Prurigo nodularis as initial presentation of metastatic transitional cell carcinoma of the bladder.  J Urol. 2002 Aug;168(2):631-2.

42. Chen PM, Yang MH, Yu IT, Lin JT, Lin YC, Fan FS, Wang WS, Yen CC, Chiou TJ, Liu JH.  Low incidence of BCL-6 gene alterations for diffuse large B-cell lymphomas in Taiwan Chinese. Cancer, 2002 May 15;94(10):2635-44.

43. Hsiao LT, Chung HM, Lin JT, Chiou TJ, Liu JH, Fan FS, Wang WS, Yen CC, Chen PM. Stevens-Johnson syndrome after treatment with STI571: a case report. Br J Haematol. 2002 Jun;117(3):620-2.